

COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Medically-Accepted Indication Prior Authorization

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name (if applicable):	
*Please note that Elixir will process the request as writte	n, including drug name, with n	o substitution.	
	☐ Expedited/Urgent		
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information		pproval. Please answer the	
tollowing que	estions and sign.		
Q1. Is this request for initial or continuing therapy?			
☐ Initial therapy	☐ Continuing therapy		
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):			
Q3. Please indicate the patient's diagnosis for the requeste	ed medication:		
Q4. Please list all other medications the patient has previously tried for the indicated diagnosis along with the dates and outcomes (e.g. ineffective, adverse reaction, etc):			
and outcomes (e.g. menective, adverse reaction, etc).			
Q5. Please provide any supporting clinical statements such	n as chart notes, lab values, adve	rse outcomes, treatment	
failures, or any other additional clinical information to suppo	ort an authorization request (if nee	eded):	
Q6. IF the request is for a compounded product, please ch	eck all that apply:		
☐ The prescriber attests that the requested		ided product contains bulk	
compounded product contains at least ONE prescription	powders	All A Control of the CAULY	
ingredient The prescriber attests that the requested	The requested compour over-the-counter ingredients	dea product contain ONLY	
compounded product is not a copy of a commercially	☐ The request is for a rene	wal and the prescriber	
23p. 23a.z. p. 23.a.z. to flot a copy of a confinitionally		a. ana are procention	



COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Medically-Accepted Indication Prior Authorization

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
available FDA-approved product Dosage form being compounded is due to the patient being unable to use the commercially available product Patient is unable to use a commercial available product due to a hypersensitivity or allergy to any of the components (i.e. dyes, preservatives, fragrances, gluten) There is a commercially available product shortage or discontinuation by the manufacturer	attests that patient has had disease stabilization or improvement with the use of this compounded product ☐ None of the above
Q7. IF the request is for a compounded product, please sp care based on credible scientific literature defined as one of the peer reviewed literature indexed in Medline CMS recognized pharmacy compendia (e.g. NCCN, Published clinical practice guidelines developed by guidelines (e.g. American Medical Association, Infectious Other None of the above Q8. If answer is OTHER, please specify below:	of the following (Check all that apply): DrugDex, and AHFS DI) multidisciplinary experts and clinicians affected by the
accepted indication. Medically accepted indications are de under the Food, Drug, and Cosmetic Act or supported by r Recognized compendia are: American Hospital Formulary Comprehensive Cancer Network (NCCN), and Clinical Phaliterature may also be used to determine medically accepted Acceptable peer-reviewed medical literature includes: American Annals of Oncology, Annals of Surgical Oncology, Biology Transplantation, British Journal of Cancer, British Journal of Cancer Research, Drugs, European Journal of Cancer, Gy Oncology, Biology and Physics, The Journal of the American Journal of the National Cancer Institute, Journal of the Natlancet, Lancet Oncology, Leukemia, The New England Jo	based on the criteria outlined in this paragraph and the libed are covered by the plan and being used for a medically fined by the plan as: Any use of a drug which is approved ecognized compendia or resources. Service Drug Information (AHFS), Micromedex, National armacology. When necessary, peer reviewed medical ed indications for anti-cancer chemotherapy requests. Erican Journal of Medicine, Annals of Internal Medicine, of Blood and Marrow Transplantation, Blood, Bone Marrow of Hematology, British Medical Journal, Cancer, Clinical enecologic Oncology, International Journal of Radiation, an Medical Association, Journal of Clinical Oncology, ional Comprehensive Cancer Network, Journal of Urology,



COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Medically-Accepted Indication Prior Authorization

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.		
Patient Name:	Prescriber Name:	
Prescriber Signature	 Date	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document